Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PDL1 Gene Mutation”

42 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 42 results

Not applicableLooking for participantsNCT07279402
What this trial is testing

TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

Who this might be right for
NSCLC Stage IVPD-L1 Gene MutationAtezolizumab+1 more
Antalya Training and Research Hospital 150
Not applicableUnknownNCT04191226
What this trial is testing

Genetic Mutation in Recurrent Cervical Cancer

Who this might be right for
Recurrent Cervical CancerNucleotide VariantCopy Number Variation+6 more
Lei Li 300
Testing effectiveness (Phase 2)UnknownNCT04940637
What this trial is testing

UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC

Who this might be right for
Lung CancerMesothelioma
University of Turin, Italy 70
Testing effectiveness (Phase 2)UnknownNCT06195683
What this trial is testing

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

Who this might be right for
Non-small Cell Lung CancerPDL1 Gene Mutation
Zhejiang Cancer Hospital 23
Testing effectiveness (Phase 2)WithdrawnNCT04470674
What this trial is testing

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Who this might be right for
Lung CancerNon-small Cell Lung CancerPD-L1 Gene Mutation+1 more
Shirish M Gadgeel
Testing effectiveness (Phase 2)Looking for participantsNCT06501391
What this trial is testing

Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis

Who this might be right for
NSCLC Stage IVBrain Metastases
Fudan University 54
Not applicableUnknownNCT03495544
What this trial is testing

Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer

Who this might be right for
Hereditary Breast Cancer
Tatarstan Cancer Center 390
Testing effectiveness (Phase 2)UnknownNCT05394233
What this trial is testing

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

Who this might be right for
Non-squamous Non-small Cell Lung CancerEGFR Gene Mutation
Sichuan Cancer Hospital and Research Institute 20
Large-scale testing (Phase 3)Looking for participantsNCT06119581
What this trial is testing

First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
Eli Lilly and Company 1,264
Testing effectiveness (Phase 2)Study completedNCT05330143
What this trial is testing

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

Who this might be right for
HIV-1-infectionHIV InfectionsPD-L1 Gene Mutation
Ascletis Pharmaceuticals Co., Ltd. 19
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05280626
What this trial is testing

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Who this might be right for
Diffuse Large B-Cell Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 100
Testing effectiveness (Phase 2)UnknownNCT03491345
What this trial is testing

K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

Who this might be right for
PD-L1 Positive Mutation TumorEBV Positive Mutation TumorMSI-H Mutation Tumor+1 more
Yonsei University 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06008093
What this trial is testing

Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04716946
What this trial is testing

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Who this might be right for
NSCLCNon-small Cell Lung CancerLung Cancer+5 more
Memorial Sloan Kettering Cancer Center 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445843
What this trial is testing

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals 95
Not applicableUnknownNCT05527808
What this trial is testing

A Single-arm Exploratory Study of Neoadjuvant Therapy

Who this might be right for
Lung Adenocarcinoma
Jun Liu 28
Testing effectiveness (Phase 2)UnknownNCT04023916
What this trial is testing

Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.

Who this might be right for
Diffuse Large B-Cell LymphomaSintilimabTP53 Mutation
Chinese Academy of Medical Sciences 30
Not applicableUnknownNCT04405661
What this trial is testing

Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC

Who this might be right for
NSCLC
Guangzhou Institute of Respiratory Disease 100
Not applicableActive Not RecruitingNCT06876402
What this trial is testing

Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Hellenic Cooperative Oncology Group 367
Testing effectiveness (Phase 2)UnknownNCT05266937
What this trial is testing

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Who this might be right for
Metastatic Breast CancerTriple Negative Breast CancerPD-L1 Gene Mutation
Consorzio Oncotech 49
Load More Results